Kanaph focuses on the research and development of innovative therapeutic molecules to provide solutions for unmet medical needs in cancer and autoimmune diseases. With both large molecule and small molecule drug discovery and development expertise, Kanaph strives to develop first-in-class and best-in-class therapies for well validated targets, each through a strategically differentiated approach. It is our goal to build a robust portfolio of oncology programs, that can be combined with one another or with existing therapeutic agents for synergistic outcomes.

TMEkine™, Kanaph's proprietary large molecule immuno-oncology platform, converts cold tumors into hot tumors for effective eradication of tumors that have evaded patients' immune systems.

Kanaph's bi-specific fusion proteins for autoimmune diseases are designed and engineered with the vision of overcoming the limitations of agents that are currently marketed or being tested in the clinic. By taking a bi-specific approach, Kanaph's programs can address the multi-factorial drivers of complement-mediated diseases.

Our small molecule drug discovery efforts include the development of novel small molecules to treat hard-to-cure cancers by targeting specific mutational signaling pathways. We are also taking novel therapeutic approaches with small molecules to remove immuno-suppressive environment created by tumors.